In addition, the treatment with lactoferrin reduces the levels of key players of inflammation and oxidative stress involved in AD pathology (e.g., serum levels of Aβ42, cholesterol, oxidative stress markers, IL-6, HSP-90, caspase-3, P-tau, tau, MAPK1, and PTEN) probably modulating the p-Akt/PTEN pathway [90]. This evidence concerns the gene LTF and Alzheimer disease.